mFOLFIRINOX: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving mFOLFIRINOX

• A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
  NCT07255404 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 24 locations
• A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
  NCT07283705 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
  NCT07671339 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
  NCT06079346 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
  NCT05968326 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 89 locations
• A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
  NCT06179160 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
  NCT06835569 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 12 locations
• Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
  NCT05179889 · Phase: Phase 2, Phase 3 · Ages: 20 Years to 75 Years · Sex: All (male and female) · 1 location
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer
  NCT06917079 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 17 locations
• Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
  NCT06572813 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
  NCT05174169 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1066 locations
• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
  NCT07166601 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma
  NCT06648434 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
  NCT06389760 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
  NCT06922591 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations

Common questions

How many recruiting trials involve mFOLFIRINOX?

15 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.